Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19327881 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | September 2025 | January 2026 | Allow | 4 | 1 | 0 | Yes | No |
| 18801407 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | August 2024 | April 2025 | Allow | 8 | 0 | 0 | Yes | No |
| 18673619 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | May 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18634259 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | April 2024 | March 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18613695 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | March 2024 | January 2026 | Allow | 22 | 2 | 0 | No | No |
| 18588513 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | February 2024 | September 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18583002 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18545487 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | December 2023 | October 2025 | Allow | 22 | 2 | 1 | No | No |
| 18507678 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | November 2023 | October 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18507660 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | November 2023 | October 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18387420 | INHIBITORS OF MENIN-MLL INTERACTION | November 2023 | December 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18500786 | SMALL MOLECULE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) INHIBITORS AND METHODS OF TREATMENT | November 2023 | September 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18386224 | BICYCLIC AMINES AS CDK2 INHIBITORS | November 2023 | July 2025 | Allow | 20 | 1 | 1 | No | No |
| 18496692 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | October 2023 | July 2024 | Allow | 9 | 0 | 0 | No | No |
| 18488626 | Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | October 2023 | July 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18487159 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | October 2023 | December 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18476141 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | September 2023 | September 2025 | Allow | 24 | 0 | 1 | Yes | No |
| 18467162 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18243068 | PYRROLO[2,3-C][1,6]NAPHTHYRIDINE-8-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 1 | Yes | No |
| 18241350 | 5-SUBSTITUTED PYRIDO[3'',4'':4',5']PYRROLO[3',2':4,5]IMIDAZO[1,2-a]PYRAZINE COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18365286 | PROTEIN KINASE B INHIBITORS | August 2023 | November 2024 | Allow | 15 | 1 | 1 | No | No |
| 18363600 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | August 2023 | May 2024 | Allow | 10 | 1 | 1 | No | No |
| 18359709 | SPIRO[BENZO[D]THIAZOLE-6 ,4'- PIPERIDINE AS ACC INHIBITORS | July 2023 | March 2026 | Allow | 32 | 1 | 0 | Yes | No |
| 18351752 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | July 2023 | May 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18347345 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | July 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18214327 | LSD DERIVATIVES, SYNTHESIS & METHOD FOR TREATMENT OF DISEASES AND DISORDERS | June 2023 | November 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 18267890 | SYNTHESIS PROCESS OF AMIDE DERIVATIVES OF HYDROXYPENICILLANIC ACID | June 2023 | February 2026 | Allow | 32 | 0 | 1 | Yes | No |
| 18207436 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | June 2023 | August 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18198646 | PROCESS FOR PREPARING (15ALPHA,16ALPHA,17BETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL MONOHYDRATE (ESTETROL MONOHYDRATE) | May 2023 | October 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18196002 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | May 2023 | December 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18143720 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18298449 | DNA Polymerase IIIC Inhibitors and Use Thereof | April 2023 | September 2025 | Allow | 30 | 1 | 1 | No | No |
| 18124827 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | March 2023 | March 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18185227 | PYRAZOLE MAGL INHIBITORS | March 2023 | December 2024 | Allow | 21 | 1 | 0 | No | No |
| 18120767 | JAK INHIBITORS AND METHODS FOR SYNTHESIZING AND USING THEREOF | March 2023 | November 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18245109 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18024612 | PROCESS FOR PREPARING (3alpha,5alpha)-3-HYDROXY-3-METHYL-PREGNAN-20-ONE (GANAXOLONE) | March 2023 | September 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18116094 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | March 2023 | March 2026 | Abandon | 36 | 2 | 1 | No | No |
| 18176389 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | February 2023 | November 2024 | Abandon | 20 | 0 | 0 | Yes | No |
| 18112699 | PROCESS FOR THE PREPARATION OF SODIUM (2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B] [1,3] OXAZEPIN-8-OLATE AND ITS POLYMORPHIC FORM | February 2023 | May 2024 | Allow | 14 | 0 | 1 | Yes | No |
| 18171798 | NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS | February 2023 | March 2026 | Allow | 37 | 2 | 1 | No | No |
| 18041731 | THERAPEUTIC PHENETHYLAMINE COMPOSITIONS AND METHODS OF USE | February 2023 | August 2024 | Allow | 18 | 4 | 1 | Yes | No |
| 18020802 | CRYSTALLINE FORMS OF CFTR MODULATORS | February 2023 | October 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18166008 | BETULASTATIN COMPOUNDS | February 2023 | November 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 18007421 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18101009 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | January 2023 | June 2024 | Allow | 16 | 0 | 1 | No | No |
| 18157783 | METHODS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS | January 2023 | September 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18096392 | FUSED HETEROAROMATIC PYRROLIDINONES | January 2023 | January 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18089971 | PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF | December 2022 | March 2026 | Abandon | 38 | 1 | 1 | Yes | No |
| 18145901 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | December 2022 | February 2026 | Allow | 38 | 2 | 0 | No | No |
| 18069646 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | December 2022 | March 2024 | Allow | 15 | 0 | 0 | No | No |
| 18086397 | Derivative of berberine, and the preparation method and application thereof | December 2022 | November 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 18083602 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | December 2022 | March 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18084208 | MORPHOLINYLPYRIDONE COMPOUNDS | December 2022 | July 2024 | Abandon | 19 | 2 | 0 | No | No |
| 18009481 | METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOF | December 2022 | March 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 18074889 | GLUCAGON RECEPTOR ANTAGONIST AND USE THEREOF | December 2022 | June 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18000016 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | November 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17924792 | CRYSTALLINE SALT OF ERIBULIN | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17983735 | Heterocyclic Compounds and Uses Thereof | November 2022 | November 2025 | Abandon | 36 | 2 | 0 | No | Yes |
| 17997983 | FREE BASE CRYSTALS | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17923002 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | November 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 18050650 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | October 2022 | August 2024 | Allow | 22 | 2 | 1 | No | No |
| 18049344 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | October 2022 | July 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17921278 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF THE RESPIRATORY TRACT INFECTIONS | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17967508 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | October 2022 | June 2024 | Allow | 20 | 1 | 0 | No | No |
| 17967483 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | October 2022 | June 2024 | Allow | 20 | 1 | 0 | No | No |
| 17916727 | VIRAL ENTRY INHIBITORS AND RNA POLYMERASE INHIBITORS | October 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17952460 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | September 2022 | May 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17914283 | NOVEL METHOD FOR PREPARING INOTODIOL | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | Yes | No |
| 17906884 | MORPHINAN ISOMERS AND THEIR STRUCTURAL MODIFICATIONS AS NMDAR ANTAGONISTS AND NEUROPLASTOGENS | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17933850 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | September 2022 | January 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 17912301 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17932876 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | September 2022 | July 2023 | Allow | 10 | 1 | 1 | No | No |
| 17910529 | PURINE COMPOUNDS FOR TREATING DISORDERS | September 2022 | November 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17939326 | ISOTOPICALLY LABELED BILE ACID DERIVATIVES | September 2022 | September 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17902159 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | September 2022 | November 2025 | Abandon | 38 | 3 | 1 | No | No |
| 17901007 | DOPAMINE-B-HYDROXYLASE INHIBITORS | September 2022 | December 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17823254 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | August 2022 | June 2025 | Allow | 34 | 3 | 1 | No | Yes |
| 17891869 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | August 2022 | July 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17887325 | MATERIAL FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS | August 2022 | December 2022 | Allow | 4 | 1 | 1 | Yes | No |
| 17818873 | STEROIDS AND METHODS OF MANUFACTURE | August 2022 | March 2025 | Allow | 31 | 3 | 1 | Yes | No |
| 17818517 | Synthesis Of Benzodiazepine Derivatives | August 2022 | September 2025 | Abandon | 38 | 4 | 0 | Yes | No |
| 17798484 | POLYMORPHS OF ELAFIBRANOR | August 2022 | September 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17878495 | ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS | August 2022 | May 2023 | Allow | 9 | 0 | 1 | Yes | No |
| 17759644 | MACROCYCLIC RIP2-KINASE INHIBITORS | July 2022 | January 2026 | Allow | 42 | 2 | 0 | No | No |
| 17874324 | Novel compounds and their use in therapy | July 2022 | January 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17873248 | NEAR-INFRARED FLUORESCENT INDICATORS FOR LYSOSOME AND APPLICATION THEREOF | July 2022 | December 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17870885 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | July 2022 | December 2024 | Allow | 29 | 4 | 1 | Yes | No |
| 17870156 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | July 2022 | February 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17870151 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | July 2022 | December 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17814224 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | July 2022 | June 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17813805 | TYK2 INHIBITORS AND USES THEREOF | July 2022 | April 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17759054 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | July 2022 | January 2026 | Abandon | 42 | 1 | 1 | Yes | No |
| 17864106 | MAP4K1 INHIBITORS | July 2022 | June 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17812310 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | July 2022 | December 2025 | Allow | 41 | 4 | 1 | Yes | Yes |
| 17810915 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | July 2022 | May 2025 | Allow | 35 | 3 | 1 | No | Yes |
| 17857149 | ENVIRONMENTALLY RESPONSIVE TRANS-2-HEXENAL SUSTAINED-RELEASE AGENT, PREPARATION METHOD, AND APPLICATION | July 2022 | October 2025 | Abandon | 39 | 3 | 1 | Yes | No |
| 17855672 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | June 2022 | October 2023 | Abandon | 16 | 0 | 1 | No | No |
| 17790042 | PROCESS FOR THE SYNTHESIS OF BUPRENORPHINE | June 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17853647 | AhR MODULATORS | June 2022 | November 2024 | Allow | 29 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOORE, SUSANNA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOORE, SUSANNA works in Art Unit 1624 and has examined 1,593 patent applications in our dataset. With an allowance rate of 66.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 32 months.
Examiner MOORE, SUSANNA's allowance rate of 66.6% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MOORE, SUSANNA receive 1.68 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MOORE, SUSANNA is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +39.2% benefit to allowance rate for applications examined by MOORE, SUSANNA. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.7% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 60.4% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 89.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.4% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 13.2% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.